- Home
- PETS vs ALXO Comparison
PETS vs ALXO Comparison
Compare PETS & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- ALXO
- Stock Information
- Founded
- PETS 1996
- ALXO 2015
- Country
- PETS United States
- ALXO United States
- Employees
- PETS N/A
- ALXO N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- ALXO Health Care
- Exchange
- PETS Nasdaq
- ALXO Nasdaq
- Market Cap
- PETS 58.9M
- ALXO 56.8M
- IPO Year
- PETS N/A
- ALXO 2020
- Fundamental
- Price
- PETS $2.82
- ALXO $1.08
- Analyst Decision
- PETS Sell
- ALXO Strong Buy
- Analyst Count
- PETS 1
- ALXO 6
- Target Price
- PETS $3.20
- ALXO $3.30
- AVG Volume (30 Days)
- PETS 92.2K
- ALXO 872.6K
- Earning Date
- PETS 11-05-2025
- ALXO 11-06-2025
- Dividend Yield
- PETS N/A
- ALXO N/A
- EPS Growth
- PETS N/A
- ALXO N/A
- EPS
- PETS 0.02
- ALXO N/A
- Revenue
- PETS $247,010,000.00
- ALXO N/A
- Revenue This Year
- PETS N/A
- ALXO N/A
- Revenue Next Year
- PETS N/A
- ALXO N/A
- P/E Ratio
- PETS $164.97
- ALXO N/A
- Revenue Growth
- PETS N/A
- ALXO N/A
- 52 Week Low
- PETS $2.72
- ALXO $0.40
- 52 Week High
- PETS $6.85
- ALXO $2.36
- Technical
- Relative Strength Index (RSI)
- PETS 50.01
- ALXO 55.71
- Support Level
- PETS N/A
- ALXO $1.01
- Resistance Level
- PETS $3.08
- ALXO $1.27
- Average True Range (ATR)
- PETS 0.10
- ALXO 0.11
- MACD
- PETS -0.12
- ALXO -0.02
- Stochastic Oscillator
- PETS 88.68
- ALXO 38.71
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.